Skip to content

A study on the mechanism of PAGLn in chronic heart failure based on the mTORC1/autophagy pathway

A study on the mechanism of PAGLn in chronic heart failure based on the mTORC1/autophagy pathway

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119174
Enrollment
Unknown
Registered
2026-02-24
Start date
2025-04-18
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure disease

Interventions

Sponsors

Shanxi Bethune Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients with heart failure: (1) aged >=18 years; signed informed consent; (2) diagnosis of heart failure confirmed by physical examination, laboratory testing, and echocardiography in accordance with the criteria of the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart failure with preserved ejection fraction (HFpEF) was defined as EF >=50%; heart failure with reduced ejection fraction (HFrEF) was defined as EF =18 years; (2) patients concurrently hospitalized in the same department who, according to ACC/AHA criteria, are in a pre-heart-failure or preclinical stage of heart failure (i.e., have HF risk factors or structural heart disease but no clinical symptoms of HF), and in whom heart failure was excluded on clinical evaluation.

Exclusion criteria

Exclusion criteria: 1.At enrollment: acute myocardial infarction, malignant (life-threatening) cardiac arrhythmias, congenital or valvular heart disease, acute cerebrovascular disease, severe infectious diseases, hematologic disorders, malignancies, or autoimmune diseases; 2.Moderate to severe renal dysfunction [eGFR <=60 mL/min/1.73 m2] or receipt of renal replacement therapy; 3.Hepatic dysfunction (Child-Pugh class A or higher); 4.Use of antibiotics within 4 weeks prior to enrollment; 5.Undergoing open-heart surgery within 4 weeks prior to enrollment; 6.Pregnancy, lactation, or planning pregnancy during the study period; 7.Inability to complete 12 months of follow-up, or presence of other major diseases or conditions that could potentially affect study outcomes.

Design outcomes

Primary

MeasureTime frame
Composite endpoint of cardiovascular death (sudden cardiac death, acute myocardial infarction, heart failure, cardiovascular surgery, or other cardiovascular causes) or heart transplantation;

Secondary

MeasureTime frame
All-cause mortality;Worsening heart failure;First hospitalization due to cardiovascular causes;

Countries

China

Contacts

Public ContactLi Li

Shanxi Bethune Hospital

15103413856@163.com+86 151 0341 3856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026